卖什么
Multimodal foundation models to predict uncollected patient biology
商业模式拆解
买家：谁掌握预算？
未核实Heads of translational medicine / pathology / biomarker R&D at pharma and biotech.
触发点：什么让他们现在购买？
Multiplex immunofluorescence is expensive, slow and consumes scarce tissue while trial biopsy requirements tighten.
工作流：什么输入变成什么输出？
Send existing H&E slides; Lattice predicts spatially resolved protein-marker maps as virtual mIF channels across an archive; optionally fine-tuned to the customer's indications and marker panel.
经济账：省了什么，怎么收费？
未核实Project-based/model access replacing wet-lab mIF assays with computation; no price figures.
渠道：怎么接触到客户？
Enterprise sales: work-email "Discuss your project" form, plus web app and docs/developers.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2026 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.